期刊文献+

临床药师参与肿瘤科乳腺癌序贯辅助化疗的实践与分析 被引量:2

Practice of Oncology Pharmacists in Sequential Chemotherapy for Breast Cancer
下载PDF
导出
摘要 从临床药师角度分析1例早期乳腺癌患者保乳术后的病情特征、治疗原则,利用药学理论和循证药学,与医师共同讨论治疗方案,并对方案进行评价与调整,从入院到出院实施药物监护计划。临床药师通过病例跟踪分析,可以发现临床药物治疗中需注意的问题,提出合理建议。此举有利于与医护人员形成综合治疗团队。 To probe the way for oncology pharmacist how to take part in making the therapy plan and how to do the medical service.Analyzing the patient's condition and principle of treatment of one case of early stage breast cancer after the breast conserving surgery,the oncology pharmacist cooperated with doctors in the chemotherapy,evaluated and adjusted the medical plan,carried out the medical service while the patient living in and after leaving the hospital as well.The oncology pharmacist could propose rational advices in order to regulate use of medicines through following the case.It is important for oncology pharmacists to merge into the doctors and nurses to form a remedial team in the integrative treatment,and clinical pharmaceutical care needs to be developed.
出处 《药学与临床研究》 2011年第1期55-57,共3页 Pharmaceutical and Clinical Research
基金 江苏省卫生厅2009年度重点科研项目(P200803)
关键词 肿瘤科 临床药师 乳腺癌 序贯辅助化疗 药学服务 Oncology pharmacist Breast cancer Sequential chemotherapy Pharmaceutical care
  • 相关文献

参考文献6

二级参考文献82

  • 1张斌,张强,赵林,龙飞,李爽,姜大庆,徐宏.乳腺癌新辅助化疗疗效的评价及影响因素分析[J].中华肿瘤杂志,2006,28(11):867-870. 被引量:44
  • 2Stewart BW, Kleihues P. World Cancer Report [M]. Geneva, Switzerland: World Health Organization, 2003.
  • 3Early Breat Cancer TrialistsI Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials [J]. Lancet, 2005,365(9742) : 1687-1717.
  • 4Early Breast Cancer Trlalists's Collaborative Group. Multi-agent chemotherapy for early breast cancer [DB/CD]. Cochrane Database Syst Rev, 2002, ( 1 ) : CD000487.
  • 5Poole CJ, Earl HM, Hiller L, et al. Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant therapy for early breast cancer[J]. N Engl J Med, 2006,355 (18): 1851-1862.
  • 6Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive Cyclophosphamide, Epirubicin, and Fluorouraeil chemotherapy compared with Cyclophosphamide, Methotrexate, and Fluorouracil in premenopausal women with node-positive breast cancer[J]. J Clin Oncol, 1998,16(8):2651-2658.
  • 7Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer [J]. J Clin Oncol, 2003,21(6):976-983.
  • 8Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after Doxorubicin plus Cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 [J ]. J Clin Oncol, 2005,23 (16) : 3686-3696.
  • 9Jones S, Holmes F, O'Shaughnessy J, et al. Extended follow- up and analysis by age of the US oncology adjuvant trial 9735 : Docetaxe[/Cyclophosphamide is associated with an OS benefit compared to Doxorubicin/Cyclophosphamide and is well- tolerated in women 65 or older. Paper presented at San Antonio Breast Cancer Symposium[C]. San Antonio, Texas, USA, 2007.
  • 10Jones SE, Savin MA, Holmes FA, et al. Phase Ⅲ trial comparing Doxorubicin plus Cyclophosphamide with Docetaxel plus Cyclophosphamide as adjuvant therapy for operable breast cancer [J]. J Clin Oncol, 2006,24(34):5381-5387.

共引文献256

同被引文献15

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部